Despite 71% of adolescents with severe alopecia achieving successful hair regrowth with its existing drug, Eli Lilly is now betting on an early-stage AI startup for hair loss treatments. This investment includes Absci's early-stage drug, ABS-201, designed using artificial intelligence tools, according to Statnews.
Eli Lilly already has a highly effective drug for hair loss, according to Investor Lilly, yet it is simultaneously investing in an unproven, early-stage AI-designed drug for the same condition. Pharmaceutical giants are increasingly prioritizing AI-driven drug discovery as a future growth engine, even when current therapies are successful.
Lilly's Established Success in Hair Loss Treatment
Eli Lilly's traditional hair loss treatment, baricitinib 4 mg, has delivered impressive results. At one year, 71% of adolescents with severe alopecia areata achieved successful scalp hair regrowth. Beyond that, 54.1% of patients saw 80% or more scalp hair coverage, 64.8% achieved significant eyebrow regrowth, and 63.3% experienced eyelash regrowth, all according to Investor Lilly. These robust clinical outcomes confirm the effectiveness of Lilly's conventional treatment, making their new AI investment a striking contrast.
AI's Transformative Power in Drug Discovery
Eli Lilly isn't just dabbling in AI for new diseases; they're actively investing in AI-driven solutions for conditions where their traditional treatments already excel. Eli Lilly's active investment in AI-driven solutions for conditions where their traditional treatments already excel reveals a profound belief in AI's transformative power, far beyond mere supplementary use. Their decision to back an early-stage AI-designed drug like ABS-201, despite baricitinib's 71% efficacy, means Eli Lilly anticipates AI can deliver profoundly superior drugs, potentially slashing discovery costs and timelines. Lilly's decision to back an early-stage AI-designed drug like ABS-201, despite baricitinib's 71% efficacy, suggests Lilly is willing to proactively cannibalize its own successful traditional drug to prevent competitors from disrupting the market first. It also shows pharmaceutical giants are ready to take substantial early-stage risks in AI drug development, even if it means potentially devaluing their own successful traditional treatments.
Eli Lilly's aggressive move into AI-designed drugs, even with existing successful treatments, suggests that by 2026, major pharmaceutical companies will likely prioritize AI as a core engine for innovation, potentially displacing even highly effective traditional therapies.
